Lilly's EloraTZP shows stronger weight-loss results than Zepbound
Eli Lilly reported stronger weight-loss results for experimental EloraTZP compared to tirzepatide alone. Shares of LLY traded down approximately 0.8%.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.